Physician-Led Health Tech Startup Scales Therapeutic Plasma Exchange (TPE) Nationwide Amid Rise in Diseases Linked to Toxins

MDLifespan's patented PlasmaXchange™ protocols remove all environmental toxins from the body which are driving chronic diseases — including the first mold detox removing 90% of mold toxins

CHICAGO, July 21, 2025 /PRNewswire/ -- MDLifespan, the nation's first and only physician-led health tech company exclusively focused on removing disease-linked toxins through advanced Therapeutic Plasma Exchange (TPE) protocols, today announced a major nationwide expansion of its patented PlasmaXchange™ platform into eight additional states, with more locations slated to open through Q3 and Q4 2025.

New MDLifespan treatment centers are now operating or in development in Florida, Illinois, Ohio, New Jersey, Arizona, Colorado, Texas, and Michigan, reinforcing the company's position as the market leader in regenerative detoxification — a category increasingly recognized as critical to longevity, disease prevention, and reproductive health.

"Environmental toxins are THE silent drivers of today's most devastating diseases — from neurodegeneration to cardiovascular disease, immune dysfunction, cancer, chronic fatigue, and infertility. MDLifespan exists to remove them," said Paul Savage, MD, founder and CEO of MDLifespan. "We are physician-led for a reason: our protocols are designed to identify and eliminate the toxins that matter most for health outcomes — not just to move blood through a machine."

Detoxification for Disease Prevention
Backed by early-stage health-tech investors and an elite network of integrative physicians, MDLifespan has emerged as a category-defining innovator in the $100+ billion personalized medicine market.

Its flagship PlasmaXchange™ protocols combine hospital-grade Therapeutic Plasma Exchange (TPE) with proprietary diagnostics and regenerative therapies to remove entrenched toxins associated with disease progression, while restoring immune, metabolic, and mitochondrial function.

Proprietary protocols — including MDL Brain, MDL Heart, MDL Immunity, MDL Cancer, MDL Longevity, and MDL Toxins — remove environmental and metabolic toxins such as microplastics, glyphosate, pesticides, PFAS, mold toxins, heavy metals, and inflammatory proteins.

A recent peer-reviewed study published in Medical Hypotheses demonstrated that MDLifespan's physician-designed protocol achieved:

• 99% reduction in phthalates
• 85% reduction in lead
• 75% reduction in glyphosate
• 95% reduction in inflammatory markers
  in healthy adults — significantly outperforming conventional approaches.

First-of-Its-Kind Mold Detox Protocol
As part of this expansion, MDLifespan has launched its newest innovation: MDL Mold PlasmaXchange™, co-developed with mold illness expert Dr. Jill Carnahan. This physician-designed protocol delivers up to 90% reduction in circulating mold toxins, compared to just ~17% with oral binders and ~30% with standard TPE protocols — setting a new benchmark for mold detoxification.

"We're not just scaling access to TPE — we're scaling measurable outcomes that matter to patients and practitioners," said Dr. Savage. "This is the future of regenerative medicine."

Learn More or Find a Location
MDLifespan's patented protocols are currently available at locations across the U.S., with more openings expected in late summer and fall 2025. Patients, practitioners, and investors can explore the growing national footprint at: https://mdlifespan.com/locations

To learn more about the science and real-world outcomes of PlasmaXchange, subscribe to The TPE Blueprint podcast or follow MDLifespan's research and patient stories at mdlifespan.com.

About MDLifespan
MDLifespan is a physician-led medical technology startup and certified Public Benefit Corporation delivering advanced detox and regenerative medicine solutions through Therapeutic Plasma Exchange (TPE). Founded by Dr. Paul Savage, MDLifespan is the first nationwide medical group focused on removing environmental toxins and reversing chronic inflammation using clinically validated, personalized protocols.

Contact:
Jessica Rafaeil
404-936-0191
[email protected]

SOURCE MDLifespan